Login
← Go Back
Neuland Laboratories
NEULANDLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Davuluri Rama Mohan Rao · MD: Davuluri Saharsh Rao · Listing date: Oct. 14, 2008 · Employees: 1427 · Hyderabad · http://www.neulandlabs.com
Stock Price vs Company Growth
1d
2.4%
1w
6.6%
1m
16.0%
3m
1.9%
6m
26.6%
1y
18.2%
5y
63.7%
10y
34.8%
all
34.9%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 19,224 2.4%
18,166
24,235
Company Overview
Sales
2,372 Cr
Growth: 42.6%
Profit after Tax
498 Cr
Growth: 36.8%
Mid Cap
24,665 Cr
P/E: 49.6x
Industry P/E: 32.5x
Fundamentals
Sales (Cr) ₹ 2,372
Growth 42.6%
EBITDA 32.2%
P/S 10.4x
Dividend 0.1%
P/E 49.6x
Book Value ₹ 1,575
PEG Ratio 1.2x
ROE 27.6%
P/B 12.5x
Shareholding Pattern
Institutions
Malabar India Fund Limited
9.95 %
Malabar Value Fund
4.29 %
Matthews India Fund
2.55 %
Icg Q Limited
1.76 %
Promoters
Ramamohan Rao Davuluri
24.97 %
Davuluri Vijaya Rao
4.78 %
Davuluri Sucheth Rao
2.63 %
Davuluri Saharsh Rao
1.98 %
Davuluri Rohini Niveditha Rao
1.27 %
Others
Mukul Mahavir Agrawal
2.34 %
Kedia Securities Private Limited
1.01 %
Iepf
0.21 %
Increase    Decrease    No change
Company Profile Detailed
The company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.Business verticalsGeneric drug substances (GDS): Manufacturing of generic, non-exclusive complex APIs.Custom manufacturing solutions (CMS): Contract development and manufacturing of NCE APIs and advanced intermediates for innovators.
Belongs to (33 Indices) view more
Investors (94)
dolly.kh...
icici.pr...
siddhart...
Followers (2)
harit
nilofer4